Ranitidine

證據等級: L5

預測適應症: 10 個

Ranitidine: From Gastric Acid Hypersecretion to Active Peptic Ulcer Disease

One-Sentence Summary

Ranitidine is a well-established histamine H2-receptor antagonist historically used globally for gastric acid-related conditions, but it currently holds no registered product license in the Philippines. The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, with 1 clinical trial and 19 publications currently supporting this direction.

Interpretive note: This prediction represents a pharmacological validation of ranitidine’s historically primary indication rather than a novel repurposing finding. The high score reflects the strength of the mechanistic signal within the knowledge graph. Global market availability has been severely impacted since 2020 due to NDMA contamination findings.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines (no license data on file)
Predicted New Indication	Active Peptic Ulcer Disease
TxGNN Prediction Score	99.89%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Ranitidine is a selective, competitive histamine H2-receptor antagonist. Although detailed MOA data is not available in the current dataset, extensive published literature confirms its mechanism: ranitidine blocks H2 receptors on gastric parietal cells, inhibiting both basal and stimulated gastric acid secretion and reducing nocturnal acid output by approximately 70%. The resulting elevation of intragastric pH creates a favorable microenvironment for ulcer healing — a well-characterised, direct pharmacological pathway requiring no inferential leaps.

The connection between ranitidine and active peptic ulcer disease is one of the most thoroughly established relationships in gastroenterology. Before proton pump inhibitors (PPIs) became the dominant standard of care, ranitidine (Zantac) was among the most widely prescribed drugs worldwide, with its primary regulatory approval covering short-term treatment of active duodenal and gastric ulcers. Pivotal RCTs published from the early 1980s onward (PMID 3909374, PMID 2877570, PMID 1863945) documented duodenal ulcer healing rates exceeding 90% at 4–8 weeks and demonstrated that maintenance therapy significantly reduced 12-month relapse rates.

The high TxGNN prediction score (99.89%) therefore reflects the robustness of the pharmacological signal within the knowledge graph — the H2 receptor → parietal cell → acid suppression → ulcer healing pathway is a direct, high-confidence node relationship — rather than an unexpected or speculative repurposing discovery. This is a case where the model performs as a validation tool, and its output is consistent with decades of clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00930670	Phase 4	Completed	320	Investigated whether PPIs and statins interfere with clopidogrel antiplatelet effects in post-PCI patients on dual antiplatelet therapy. Ranitidine was not the primary investigational drug, and this trial provides no direct efficacy data for ranitidine in active PUD.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3909374	1985	RCT	Scand J Gastroenterol	Ranitidine 300 mg/day in 151 patients (duodenal, prepyloric, and gastric ulcers): healing rates of 91% for duodenal ulcer at 4 weeks. Maintenance therapy (100–150 mg nightly) significantly delayed 1-year relapse vs placebo.
2877570	1986	RCT	Am J Med	Large multicenter double-blind international trial (n=1,031; 68 investigators in 19 countries): famotidine vs ranitidine in endoscopically confirmed active duodenal ulcer — equivalent healing efficacy established across a large, diverse population.
3104657	1986	RCT	Klinische Wochenschrift	Rioprostil (prostaglandin E1 analogue) vs ranitidine 300 mg nightly in duodenal ulcer healing; ranitidine served as the efficacy comparator benchmark. Discusses acid suppression depth and gastrin elevation as trade-offs.
1863945	1991	RCT	Clin Ther	Multicenter double-blind trial (n=160): famotidine 40 mg vs ranitidine 300 mg nightly for active duodenal ulcer. Healing confirmed endoscopically at 8 weeks: 94% (famotidine) vs 80% (ranitidine); 6-month maintenance data provided.
2491360	1989	RCT	J Gastroenterol Hepatol	Omeprazole (10 mg or 20 mg QD) vs ranitidine (150 mg BID) in active duodenal ulcer (n=270) with weekly endoscopy. Ranitidine as active comparator; prospective collection of 46 potential prognostic factors for healing.
6317325	1983	Drug Review	Drug Intell Clin Pharm	Early FDA-approval narrative review: ranitidine is 4–10× more potent than cimetidine on a molar basis. Summarises clinical trial evidence supporting approval for short-term treatment of active duodenal ulcer and gastric hypersecretory conditions.
6317740	1983	Drug Review	J Clin Gastroenterol	Comparative pharmacodynamics and pharmacokinetics of ranitidine vs cimetidine. Ranitidine 6–8× more potent for gastric acid suppression; longer duration of action; clinical significance of differences outlined.
1976583	1990	Review	Hepato-gastroenterology	Comprehensive review: inhibition of nocturnal and 24-hour intragastric acidity is the key factor predicting ulcer healing. Compares H2 blockers including ranitidine and famotidine on pH control, pepsin inhibition, and healing outcomes.
12751338	2003	Clinical Trial	São Paulo Med J	Ranitidine bismuth citrate + clarithromycin 7-day regimen for H. pylori eradication in Brazilian peptic ulcer patients. Supports ranitidine-based combination therapy as a valid H. pylori treatment platform.
18493408	1996	Clinical Study	Diagn Ther Endosc	Prospective endoscopic study of PUD during Ramadan fasting (n=23): ranitidine 150 mg BID at meal breaks maintained ulcer healing in adherent patients; non-adherent patients showed deterioration. Real-world dosing compliance data.

Philippines Market Information

Ranitidine has no registered products with the Philippine Food and Drug Administration (FDA Philippines). There are currently 0 active drug licenses on file for this compound.

This absence of Philippines registration is consistent with the global market situation: between 2019 and 2020, regulatory agencies including the US FDA, EMA, and Health Canada identified unacceptable levels of N-nitrosodimethylamine (NDMA) — a probable human carcinogen — in ranitidine formulations. This led to voluntary recalls by manufacturers worldwide and the withdrawal of ranitidine from most major regulated markets. As a result, ranitidine cannot currently be assessed for the Philippines market in the same way as an active, registered compound.

Safety Considerations

Please refer to the package insert for safety information.

Critical regulatory context: Ranitidine-containing products were recalled globally in 2020 following detection of NDMA contamination above the acceptable daily intake (ADI) threshold. Any future clinical consideration would require verification of an NDMA-free or NDMA-below-ADI formulation from a certified manufacturer, followed by regulatory re-submission. Package insert warnings, contraindications, and drug interaction data are not available in the current dataset and must be obtained from the original labelling documentation.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite an extensively documented evidence base confirming ranitidine’s efficacy in active peptic ulcer disease (L1 — multiple large completed Phase 3 RCTs), the drug is not registered in the Philippines and was subject to global market withdrawal due to NDMA contamination. In the current landscape, PPIs (omeprazole, esomeprazole, pantoprazole) have largely superseded H2 blockers as first-line therapy, further reducing the urgency of ranitidine re-entry. Proceeding requires resolution of both formulation safety and regulatory standing before any clinical pathway can be mapped.

To proceed, the following is needed:

Formulation safety confirmation: Certified NDMA-free or NDMA-below-ADI ranitidine formulation from an approved manufacturer, verified by validated analytical methods
Complete safety documentation: Package insert warnings, contraindications, and comprehensive drug-drug interaction data (all currently unavailable in this dataset)
Mechanism of action documentation: Full MOA description from DrugBank or equivalent source for inclusion in the regulatory dossier
Philippines FDA regulatory strategy: Assessment of the re-registration pathway under FDA Philippines requirements, including whether a new NDA or abbreviated submission applies
Comparative effectiveness analysis: Updated head-to-head comparison vs current Philippines standard of care (PPI-based regimens and H. pylori eradication protocols) to establish clinical positioning
H. pylori co-therapy evaluation: Given that H. pylori eradication is now the definitive treatment for most peptic ulcers, clarify whether ranitidine bismuth citrate formulations (which have a distinct regulatory history) offer any pathway advantage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.